By inhibiting VEGF and other pro-angiogenic factors, PI3K inhibitors disrupt the delicate balance between stimulators and inhibitors of angiogenesis, thereby inhibiting the formation of new blood vessels required for tumor growth and progression. Here, PIK3CB is linked to neoplasm.